Clinical bottom line
Low-dose naltrexone (LDN) is a putative therapeutic candidate for managing symptoms of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in primary care. Emerging evidence suggests LDN may modulate neuroimmune pathways implicated in ME/CFS, potentially reducing fatigue and pain severity. However, current data are limited by small sample sizes, heterogeneous patient populations, and a paucity of randomized controlled trials. LDN use in ME/CFS remains experimental and warrants cautious consideration alongside established management strategies.
What the evidence shows
ME/CFS is a complex, multisystem disorder characterized by persistent fatigue, post-exertional malaise, cognitive dysfunction, and chronic pain. Its pathophysiology is incompletely understood but likely involves immune dysregulation, neuroinflammation, and altered central nervous system signaling.
LDN, typically dosed at 1–5 mg daily, is hypothesized to exert therapeutic effects via transient opioid receptor blockade leading to upregulation of endogenous endorphins and modulation of microglial activation. This mechanism may attenuate neuroinflammation and improve symptom burden in ME/CFS.
Polo et al. (2019) conducted a small open-label study assessing LDN in ME/CFS patients, reporting improvements in fatigue and quality of life measures, though the lack of a control group limits causal inference. Bolton et al. (2020) presented a case report illustrating symptom improvement with LDN in a patient with ME/CFS, supporting its potential utility but underscoring the need for controlled trials.
More recently, Löhn et al. (2024) identified a potential pathophysiological role for the TRPM3 ion channel in ME/CFS and proposed that LDN’s modulation of this channel may contribute to symptom relief. This mechanistic insight provides a biological rationale for LDN’s effects but remains hypothesis-generating.
Systematic reviews of LDN in chronic pain conditions, which share symptom overlap with ME/CFS, suggest modest benefit with a favorable safety profile (Bostick et al., 2019; Radi et al., 2023). However, direct evidence in ME/CFS is sparse.
Caveats and uncertainty
The evidence base for LDN in ME/CFS is limited by small sample sizes, lack of randomized placebo-controlled trials, and heterogeneity in dosing regimens and outcome measures. Most studies are observational or case reports, which are vulnerable to bias and placebo effects.
ME/CFS itself is a clinically heterogeneous syndrome without universally accepted diagnostic biomarkers, complicating patient selection and response assessment. The long-term safety and efficacy of LDN in this population remain unclear.
Potential adverse effects of LDN are generally mild but include sleep disturbances and gastrointestinal symptoms. Clinicians should weigh these risks against uncertain benefits.
Given these limitations, LDN should not replace established supportive care and symptom management approaches but may be considered as an adjunct in selected patients after thorough discussion.
How this may change practice
Primary care clinicians managing ME/CFS may encounter patients interested in LDN as an experimental therapy. Awareness of the current evidence and its limitations can facilitate informed shared decision-making.
LDN could be considered on a case-by-case basis for patients with refractory symptoms, particularly chronic pain and fatigue, who have exhausted conventional options. Initiation should involve clear communication about the experimental nature of treatment, expected benefits, and potential side effects.
Clinicians should monitor patients closely for response and tolerability and remain vigilant for emerging high-quality evidence that may clarify LDN’s role.
Further research, including randomized controlled trials and biomarker studies, is needed to establish efficacy, optimal dosing, and patient selection criteria.